- 07 June | Open Orientation for Current Affairs for Mains 2026 Click Here to register →
- 07 June | Sociology Optional Strategy Session with AIR 10 Ujjwal Priyank Click Here to register →
- 07 June | Anthropology Optional Strategy Session with AIR 120 Anurag Singh Click Here to register →
- 08 June | Geography Optional Strategy Session with AIR 39 Rohin Kumar Click Here to register →
Contents
What is the News?
After the U.S. and Canada, India has reported the first case of Fournier’s Gangrene from Type 2 diabetes patients using sodium-glucose cotransporter-2 (SGLT2) inhibitors.
What is Fournier’s Gangrene?
Fournier’s gangrene is also called necrotizing fasciitis (flesh-eating disease). It is a serious bacterial infection that affects the genitals and areas around the genitals.
The infection commonly occurs in older men, but it can also occur in women and children.
What is the relation between Fournier’s Gangrene and Diabetes medication?
Sodium-glucose cotransporter-2(SGLT2) inhibitors (a class of Type 2 diabetes medication) are recommended as preferred add-on oral antidiabetic drugs(OADs) after metformin. This is preferred for Type-2 diabetes mellitus (T2DM) patients with cardiovascular disease, heart failure (HF) and chronic kidney disease(CKD).
However, several diabetic patients taking the SGLT2 inhibitor drugs have been infected by Fournier’s Gangrene. Recently, India has reported the first case of Fournier’s Gangrene from this diabetes medication.
What are the steps taken by the Government after this?
Central Drugs Standard Control Organization (CDSCO) has requested all State Drug Controllers to direct the manufacturers of SGLT2 inhibitor class drugs, named Canagliflozin, Dapagliflozin and Empagliflozin under their jurisdiction to include warnings in the package.
Source: This post is based on the article “First cases of infection from diabetes medication in India” published in The Hindu on 4th April 2022.
